Managing HIV infection appears to exact a hidden cellular toll that traditional cardiovascular medications might help address. While modern antiretroviral therapy has transformed HIV from a fatal diagnosis to a manageable chronic condition, emerging evidence suggests that people living with HIV experience accelerated biological aging that increases their cardiovascular risk—a phenomenon that could potentially be mitigated through targeted interventions.
A pilot analysis of 99 HIV patients from the REPRIEVE cardiovascular prevention trial revealed that pitavastatin, a cholesterol-lowering statin, significantly slowed the pace of cellular aging over 24 months. Using advanced epigenetic clocks that measure DNA methylation patterns, researchers found that while placebo recipients showed continued acceleration in their biological aging rate (measured by DunedinPACE), those receiving pitavastatin maintained stable aging velocity. Notably, all participants entered the study with substantial epigenetic age acceleration—a median of 7.08 years beyond their chronological age.
This finding extends beyond statins' established cardiovascular benefits and suggests potential anti-aging properties in immunocompromised populations. The DunedinPACE metric specifically tracks multi-organ decline associated with aging, making this stabilization particularly relevant for long-term health outcomes. However, the study's small sample size and 24-month timeframe limit broader conclusions about statins as longevity interventions. The research also raises intriguing questions about whether similar epigenetic benefits might occur in HIV-negative populations or with other statin formulations. While promising, these preliminary results require validation in larger cohorts before fundamentally altering our understanding of how cholesterol medications might influence biological aging processes.
